Shares of Cardiff Oncology Inc. were lower in Monday’s after-hours market, following the company’s announcement that it is planning a conduct a Phase 2 trial of onvansertib in combination in certain types of metastatic colorectal cancer.
The company also said after a review of clinical data in metastatic castrate-resistant prostate cancer, it will not independently fund any future clinical activities in mCRPC.
Cardiff Oncology said based on current expectations and projections, its current cash resources are sufficient to fund its operations into 2025.
At 4:56 p.m. ET, the company’s shares were trading 19% lower at $2.60 a share. The stock finished the day’s regular session with a 10.69% gain, closing at $3.21 a share.